Whether they're analyzing checkpoint inhibitors, CAR T cells, or combination regimens, pediatric cancer researchers must carefully consider which targets and drugs to trial.
Funded projects will look at the combination of imaging and liquid biopsies for monitoring cancer patient responses and the emergence of treatment resistance.
At the NCI's Childhood Cancer Data Initiative Symposium, speakers emphasized measures such as data harmonization and the need for longitudinal data collection.
The DoD and VA-led initiative is moving beyond its initial focus on lung cancer to add analyses of multiple cancer types and a prospective, multisite study.
Combined DNA/RNA-seq efforts in various settings could lead to new ways of treating kids with drugs meant for adults or to the development of new therapies.
